Piramal Pharma Solutions unveils expanded ADC facility in Scotland amid growing market demand
Piramal Pharma Solutions (PPS), a prominent Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (PPL) has opened its expanded antibody-drug conjugate (ADC) manufacturing facility in Grangemouth, Scotland, UK. This expansion marks a significant step in addressing the growing global demand for ADC manufacturing.
Dignitaries Attend Ribbon-Cutting Ceremony
The ribbon-cutting ceremony, formally commissioning the facility, was attended by Adrian Gillespie, Chief Executive of Scottish Enterprise, and key representatives from Piramal, including Chairperson Nandini Piramal, CEO Peter DeYoung, and other senior members. This event underscores the importance of the facility to the Scottish life sciences sector.
Expansion Enhances ADC Manufacturing Capacity
Piramal Pharma Solutions, a global leader in ADC development and manufacturing, has enhanced the site’s capacity by approximately 70 to 80 percent. The expansion includes two new manufacturing suites, complementing the existing three, and involves a £45 million investment. The funding sources include a Scottish Enterprise government grant, a bank loan, customer co-investment, and internal accruals.
Innovative ADC Manufacturing Hub Launched by Piramal Pharma in Grangemouth, Scotland
Benefits for Customers and Patients
The primary beneficiaries of this expansion are Piramal’s customer base and the patients they serve. The enhanced site supports the full life cycle of ADC development and manufacturing, including the company’s ADCelerate™ solution for rapid early-stage ADC drug development. This integrated offering simplifies and speeds up the development process.
Site Expansion and Future Enhancements
The site expansion also features a dedicated customer experience center, new Quality Control laboratories, warehousing, office space, and supporting utilities. The facility, designed for future expansions, may include a new sterile fill/finish suite and additional large-scale manufacturing suites.
Comments from Piramal and Scottish Enterprise Executives
Peter DeYoung, CEO of Piramal Pharma Solutions, highlighted the expansion’s role in meeting the growing demand for large and commercial-scale ADC manufacturing. Adrian Gillespie, Chief Executive of Scottish Enterprise, celebrated Piramal’s investment into Scotland’s life sciences sector, noting the high-quality jobs created and the company’s pioneering work in ADCs.
The Significance of the £45m Investment
The opening of the expanded ADC manufacturing facility in Grangemouth represents the culmination of a £45 million investment, supported by a £2.4 million Scottish Enterprise grant. This investment not only addresses the rapidly growing demand for ADC manufacturing but also signifies Piramal’s commitment to innovation and excellence in the pharmaceutical industry.